Suggestions
David Benshoof Klein
Founder & CEO of Click Therapeutics
Professional Background
David Benshoof Klein stands at the forefront of healthcare innovation as a distinguished entrepreneur and thought leader in the life sciences industry. With over 20 years of dedicated experience, David has a rich background that seamlessly blends business acumen and the cutting-edge intersection of technology and healthcare. In 2012, recognizing the transformative potential of smartphones in influencing behavior and cognition, David embarked on a mission to pioneer novel, patient-centric digital treatment solutions.
David's vision materialized with the foundation of Click Therapeutics, a trailblazing company dedicated to developing, validating, and commercializing software as prescription medical treatments. The company's early achievements include the development of Rejoyn™, a groundbreaking digital therapeutic for the adjunctive treatment of major depressive disorder symptoms, and the distinction of being the first of its kind to receive FDA authorization. Click Therapeutics is currently pushing the boundaries of medical innovation by advancing digital therapeutics in various fields, such as psychiatry, neurology, oncology, immunology, and cardiometabolic diseases.
David's commitment to evidence-based medicine ensures that Click Therapeutics adheres to the highest standards of research and development. He ardently believes that the integration of software with traditional pharmaceutical therapies will redefine standards of care, consequently enhancing patient access to essential health treatments on a global scale.
Education and Achievements
David Klein's academic journey commenced at Brandeis University where he earned his bachelor’s degree, cultivating a strong foundation in his fields of interest. His educational pursuits expanded internationally, including studies at the Pardes Channa Agricultural School in Israel and the California International School in Hong Kong, as well as at the prestigious Stuyvesant High School in New York City.
In addition to his educational background, David has held prominent roles across various organizations in the healthcare sector. His tenure as the Managing Director at Opus Point Partners was marked by the creation, financing, and management of over ten science companies, including notable firms like Cougar Biotechnology, Chelsea Therapeutics, and TG Therapeutics. Each venture contributed significantly to his comprehensive understanding of the biosciences landscape.
In recognition of his impressive career accomplishments, David was honored by Goldman Sachs as one of the 100 most intriguing entrepreneurs at the annual Builders and Innovators conference in 2019. This accolade highlighted David's entrepreneurial spirit and his ability to bring innovative ideas to fruition in the competitive healthcare landscape.
Contributions to Academia
In addition to his impactful corporate endeavors, David Klein is a respected voice in academia. As a guest faculty member, he extends his expertise to the Biotechnology Program at Columbia University, NYU Stern School of Business, and Columbia Business School. His involvement in these institutions underscores his commitment to nurturing the next generation of innovators in the life sciences and technology sectors.
Personal Interests and Community Engagement
Outside of his professional engagements, David is a passionate art enthusiast, dedicating time and resources to the promotion of contemporary art. He co-founded the Eli Klein Gallery, which has risen to prominence as one of America's leading contemporary Chinese art galleries. David's contribution to the arts exemplifies his belief in cultural enrichment and community involvement beyond the realm of medicine.
In summary, David Klein is a transformative figure in healthcare innovation, continuously striving to leverage technology for the betterment of patient outcomes. His entrepreneurial ventures and academic contributions reflect a deep-seated commitment to enhancing the future of medical care through innovative solutions and rigorous standards.
